Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-09-14 Sale | 2023-09-18 4:32 pm | NeuBase Therapeutics Inc. | NBSE | Symetryx Corp 10% Owner | 282,445 | $1.3299 | $375,620 | 0 (Direct) | View |
| 2023-09-07 Sale | 2023-09-11 5:08 pm | NeuBase Therapeutics Inc. | NBSE | Symetryx Corp 10% Owner | 207,075 | $1.6261 | $336,731 | 472,926 (Direct) | View |
| 2023-09-01 Purchase | 2023-09-07 5:19 pm | NeuBase Therapeutics Inc. | NBSE | Symetryx Corp 10% Owner | 61,076 | $0.978 | $59,732 | 680,081 (Direct) | View |
| 2022-03-30 Purchase | 2022-04-01 4:16 pm | NeuBase Therapeutics Inc. | NBSE | Mann William Roland Chief Operating Officer | 6,200 | $1.92 | $11,904 | 11,200 (Direct) | View |
| 2022-03-18 Purchase | 2022-03-21 4:06 pm | NeuBase Therapeutics Inc. | NBSE | Branning Todd P. Chief Financial Officer | 10,000 | $1.81 | $18,100 | 30,000 (Direct) | View |
| 2022-03-16 Purchase | 2022-03-18 4:11 pm | NeuBase Therapeutics Inc. | NBSE | Branning Todd P. Chief Financial Officer | 20,000 | $1.68 | $33,600 | 20,000 (Direct) | View |
| 2022-03-01 Purchase | 2022-03-07 7:13 pm | NeuBase Therapeutics Inc. | NBSE | RICHMAN ERIC I Director | 3,880 | $1.6372 | $6,352 | 72,707 (Indirect Direct) | View |
| 2021-06-18 Purchase | 2021-06-21 11:03 am | NeuBase Therapeutics Inc. | NBSE | GOLDSTEIN DOV A MD Director | 8,000 | $4.75 | $38,000 | 30,000 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2023-09-18 Ownership | 2023-09-20 8:42 pm | N/A N/A | NeuBase Therapeutics Inc. | NBSE | Symetryx Corp Shiff Aleta Shiff Barry no longer 10% Owner | 0 | $0 | 192,481 (Direct) | View |
Ownership(A) | 2023-09-12 5:20 pm | N/A N/A | NeuBase Therapeutics Inc. | NBSE | Symetryx Corp Shiff Barry Shiff Aleta 10% Owner | 0 | $0 | 190,481 (Direct) | View |
Ownership | 2023-09-01 2:51 pm | N/A N/A | NeuBase Therapeutics Inc. | NBSE | Symetryx Corp 10% Owner | 0 | $0 | 618,925 (Direct) | View |
| 2023-08-02 Exercise | 2023-08-04 4:39 pm | N/A N/A | NeuBase Therapeutics Inc. | NBSE | Stephan Dietrich A Founder and CEO 10% Owner | 93,234 | $0.022 | 238,162 (Direct) | View |
| 2023-08-02 Exercise | 2023-08-04 4:39 pm | 2019-07-12 2023-12-31 | NeuBase Therapeutics Inc. | NBSE | Stephan Dietrich A Founder and CEO 10% Owner | 93,234 | $0 | 238,162 (Direct) | View |
| 2023-03-16 Option Award | 2023-03-17 4:11 pm | N/A N/A | NeuBase Therapeutics Inc. | NBSE | Branning Todd P. Chief Financial Officer | 54,200 | $0 | 84,200 (Direct) | View |
| 2023-03-16 Option Award | 2023-03-17 4:11 pm | N/A N/A | NeuBase Therapeutics Inc. | NBSE | Stephan Dietrich A CEO and Director 10% Owner | 153,000 | $0 | 2,898,594 (Direct) | View |
| 2023-02-13 Exercise | 2023-02-15 7:30 pm | 2019-07-12 2023-12-31 | NeuBase Therapeutics Inc. | NBSE | Stephan Dietrich A President and CEO 10% Owner | 655,000 | $0 | 4,610,274 (Direct) | View |
| 2022-11-03 Option Award | 2022-11-04 5:00 pm | N/A 2032-11-03 | NeuBase Therapeutics Inc. | NBSE | Branning Todd P. Chief Financial Officer | 200,000 | $0 | 200,000 (Direct) | View |
| 2022-09-28 Exercise | 2022-09-30 7:45 pm | 2019-07-12 2023-12-31 | NeuBase Therapeutics Inc. | NBSE | Stephan Dietrich A CEO 10% Owner | 750,000 | $0.0011 | 4,610,274 (Direct) | View |
| 2022-09-09 Option Award | 2022-09-12 5:01 pm | N/A 2032-09-09 | NeuBase Therapeutics Inc. | NBSE | RICHMAN ERIC I Director | 37,600 | $0 | 37,600 (Direct) | View |
| 2022-09-09 Option Award | 2022-09-12 5:01 pm | N/A 2032-09-09 | NeuBase Therapeutics Inc. | NBSE | PRENDERGAST FRANKLYN G Director | 37,600 | $0 | 37,600 (Direct) | View |
| 2022-09-09 Option Award | 2022-09-12 5:01 pm | N/A 2032-09-09 | NeuBase Therapeutics Inc. | NBSE | McDougall Gerald J Director | 37,600 | $0 | 37,600 (Direct) | View |
| 2022-09-09 Option Award | 2022-09-12 5:00 pm | N/A 2032-09-09 | NeuBase Therapeutics Inc. | NBSE | GOLDSTEIN DOV A MD Director | 37,600 | $0 | 37,600 (Direct) | View |
| 2022-09-09 Option Award | 2022-09-12 5:00 pm | N/A 2032-09-09 | NeuBase Therapeutics Inc. | NBSE | Ende Eric J Director | 37,600 | $0 | 37,600 (Direct) | View |
| 2022-01-24 Option Award | 2022-01-25 2:03 pm | N/A 2032-01-24 | NeuBase Therapeutics Inc. | NBSE | Mann William Roland Chief Operating Officer | 60,180 | $0 | 60,180 (Direct) | View |
| 2022-01-24 Option Award | 2022-01-25 2:00 pm | N/A 2032-01-24 | NeuBase Therapeutics Inc. | NBSE | Rojas-Caro Sandra Chief Medical Officer | 44,592 | $0 | 44,592 (Direct) | View |
| 2022-01-24 Option Award | 2022-01-25 1:50 pm | N/A 2032-01-24 | NeuBase Therapeutics Inc. | NBSE | Stephan Dietrich A President and CEO 10% Owner | 306,000 | $0 | 306,000 (Direct) | View |
| 2022-01-10 Option Award | 2022-01-10 7:19 pm | N/A 2032-01-10 | NeuBase Therapeutics Inc. | NBSE | Branning Todd P. Chief Financial Officer | 300,000 | $0 | 300,000 (Direct) | View |
| 2021-12-31 Exercise | 2022-01-05 9:45 pm | 2019-07-12 2028-12-31 | NeuBase Therapeutics Inc. | NBSE | Stephan Dietrich A President and CEO 10% Owner | 42,250 | $0.001 | 4,610,274 (Direct) | View |
| 2022-01-01 Option Award | 2022-01-05 4:05 pm | N/A 2032-01-01 | NeuBase Therapeutics Inc. | NBSE | Ende Eric J Director | 165,803 | $0 | 165,803 (Direct) | View |
| 2021-08-16 Option Award | 2021-09-24 5:03 pm | N/A 2031-08-16 | NeuBase Therapeutics Inc. | NBSE | Mann William Roland COO | 25,000 | $0 | 25,000 (Direct) | View |
| 2021-08-19 Option Award | 2021-09-17 4:17 pm | N/A 2031-08-19 | NeuBase Therapeutics Inc. | NBSE | McDougall Gerald J Director | 38,135 | $0 | 38,135 (Direct) | View |
| 2021-08-19 Option Award | 2021-09-17 4:17 pm | N/A 2031-08-19 | NeuBase Therapeutics Inc. | NBSE | GOLDSTEIN DOV A MD Director | 38,135 | $0 | 38,135 (Direct) | View |
| 2021-08-19 Option Award | 2021-09-17 4:17 pm | N/A 2031-08-19 | NeuBase Therapeutics Inc. | NBSE | PRENDERGAST FRANKLYN G Director | 38,135 | $0 | 38,135 (Direct) | View |
| 2021-08-19 Option Award | 2021-09-17 4:16 pm | N/A 2031-08-19 | NeuBase Therapeutics Inc. | NBSE | RICHMAN ERIC I Director | 38,135 | $0 | 38,135 (Direct) | View |
| 2021-05-24 Option Award | 2021-05-25 4:13 pm | N/A 2031-05-24 | NeuBase Therapeutics Inc. | NBSE | Rojas-Caro Sandra Chief Medical Officer | 280,000 | $0 | 280,000 (Direct) | View |
| 2021-05-24 Option Award | 2021-05-25 4:12 pm | N/A 2031-05-24 | NeuBase Therapeutics Inc. | NBSE | Motesharei Kianoush See Remarks | 250,000 | $0 | 250,000 (Direct) | View |
| 2021-05-11 Option Award | 2021-05-13 6:03 pm | N/A 2031-05-11 | NeuBase Therapeutics Inc. | NBSE | McDougall Gerald J Director | 92,219 | $0 | 92,219 (Direct) | View |